← FDA DRUG APPROVALS

FDA NDA · NDA202428

TAZAROTENE

Sponsor: MAYNE PHARMA

APPLICATION
NDA202428
TYPE
NDA
ORIGINAL APPROVAL
2012-05-11
LATEST ACTION
2012-05-11
ROUTE
TOPICAL
DOSAGE FORM
AEROSOL, FOAM
MARKETING STATUS
Prescription

Products

FABIOR · ReferencePrescription
TAZAROTENE 0.1% · AEROSOL, FOAM · TOPICAL

Approval history

2012-05-11Type 3 - New Dosage Form · Original · standard — Label ↗AP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →